|
 |
RofecoxibThis page contains recent news articles, when available, and an overview of Rofecoxib but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Rofecoxib (when available) Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Rofecoxib is used for its anti-inflammatory, analgesic, and antipyretic activities in the management of osteoarthritis (OA) and for the treatment of dysmenorrhea or acute pain. Unlike celecoxib, Rofecoxib lacks a sulfonamide chain and does not require CYP450 enzymes for metabolism. For the treatment of osteoarthritis, acute pain in adults and menstrual pain Mechanism Of Action: Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane. Rofecoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, important for the mediation of inflammation and pain. Unlike non-selective NSAIDs, Rofecoxib does not inhibit platelet aggregation. News Articles on Rofecoxib COX-2-Hemmer könnte Hautkrebs vorbeugen - 05 Jan 2010 ...nachdem die Vioxx®-Affäre ein erhöhtes Risiko von Herz-Kreislauf-Erkrankungen unter dem COX-2-Inhibitor Rofecoxib zutage gefördert hatte (Im Gegensatz ... Deutsches Ärzteblatt Common anti-inflammatory drug could help prevent skin cancers, Stanford ... - Jan 4, 2010 Rofecoxib was withdrawn from the market by Merck in 2004, and Tang's trial was discontinued that year in response to ongoing concerns about long-term ... EurekAlert (press release) Marijuana safer than prescription drugs - Dec 10, 2009 ...information about new research by the FDA that supported previous findings of increased risk of heart attack among rofecoxib users (Grassley, 2004). ... NewsLanc Cox-2 Inhibitor Blunts Aspirin's Cardioprotection - Dec 16, 2009 Although another coxib, rofecoxib (Vioxx) famously was pulled from the market in 2004 because of its cardiovascular risk, celecoxib was assumed to be safe ... MedPage Today In re: Vioxx Class Cases - Dec 16, 2009 The second COX-2 inhibitor was rofecoxib, which was marketed by Merck under the name Vioxx. It was subsequently determined that, although Vioxx inhibited ... Leagle, Inc. Administration Files Amicus Brief in Shareholder Suit Against Merck - Nov 3, 2009 The brief filed by Solicitor General Elena Kagan supports the shareholders' assertion that they did not file the Vioxx (rofecoxib) lawsuit too late, ... FDA news (subscription) Adverse Events in Randomized Trials Neglected, Restricted, Distorted, and Silenced - Oct 26, 2009 Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. ... Archives of Internal Medicine EPHA Briefing : Proposed Directive on Pharmacovigilance - Nov 5, 2009 Recent examples include rofecoxib (Vioxx®), a painkiller with cardiovascular side effects in 2004 and rimonabant (Accomplia®) an anti-obesity drug with ... European Public Health Alliance Ibuprofen link to heart attack risk - Jun 10, 2005 The increased risk of a heart attack for those taking rofecoxib was 32 per cent ... For those who had taken rofecoxib the figure was one patient at risk for ... Telegraph.co.uk New Rofecoxib Data Will Help Inform Treatment Decisions With Other … - Oct 14, 2008 October 14, 2008 — New results from the extended follow-up of the Adenomatous Polyp Prevention on Vioxx (APPROVE) trial provide a more complete assessment ... Medscape Will rofecoxib be making a come back? - Feb 18, 2005 Gaithersburg, MD - Could rofecoxib (Vioxx, Merck) be making a comeback? Merck stunned the US Food and Drug Administration committees reviewing the ... Medscape Merck to Pay $4.85 Billion to Settle Most Vioxx (Rofecoxib) Cases - Nov 9, 2007 By Peggy Peck, Executive Editor, MedPage Today. WHITEHOUSE STATION, NJ, Nov. 9 -- Merck has agreed to pay $4.85 billion to settle the majority of pending ... MedPage Today US doctor: Rofecoxib helps beat the 'Yom Kippur headache' - Sep 29, 2006 By Relly Sa'ar. People who get severe headaches brought on by fasting no longer need to fear Yom Kippur, according to Dr. Michael Drescher, associate chief ... Ha'aretz Can rofecoxib delay a diagnosis of Alzheimer's disease in patients... - Jul 12, 2005 Thal LJ et al. (2005) A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30: 1204–1215 ... Nature.com Short-term Use of Rofecoxib May Increase Cardiovascular Risk - Jun 28, 2006 June 28, 2006 — On June 26, the New England Journal of Medicine (NEJM) posted online an unsigned correction notice regarding the Adenomatous Polyp ... Medscape Aggressive drug marketing may endanger people-study - Dec 2, 2008 For example, Merck & Co Inc's anti-inflammatory drug Vioxx, or rofecoxib, had been tried by 20 million patients before it was withdrawn in 2004 because of ... Forbes … modelling of the enterohepatic recirculation of diclofenac and... - Jul 30, 2007 The pharmacokinetics of diclofenac and rofecoxib was characterized in male rats ... For rofecoxib, EHC modelling required a conversion compartment with ... Nature.com Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of … - Feb 1, 2005 Stephen E. Kimmel, MD, MSCE; Jesse A. Berlin, ScD; Muredach Reilly, MB; Jane Jaskowiak, BSN, RN; Lori Kishel, MS; Jesse Chittams, MS; and Brian L. Strom, ... ACP Observer Study says Vioxx danger begins earlier than stated - Jul 25, 2007 Although the median duration of treatment was only 7.4 months, the researchers concluded that Vioxx, known generically as rofecoxib, was still associated ... Reuters UK Rofecoxib data called into question - Dec 9, 2005 Relevant data on cardiovascular outcomes had been deleted from the VIGOR manuscript prior to its submission to the journal. Boston, MA - In a rare move, ... Medscape Risk of Death From Vioxx In Clinical Trials May Have Been … - Apr 15, 2008 The documents became available during litigation related to rofecoxib involving ... Rofecoxib is a nonsteroidal anti-inflammatory drug (NSAID) developed by ... SeniorJournal.com Rofecoxib significantly reduces the risk of recurrence of colorectal... - Aug 30, 2006 Bethesda, MD (August 30, 2006) ñ The use of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VioxxÆ) reduces the risk of colorectal adenomas, according to ... PsychCentral.com More Evidence of COX-2 Inhibitor Risks - Vioxx (rofecoxib) Colorectal... - Feb 15, 2005 The studies report increased cardiovascular event risk seen with each of three agents: Vioxx (rofecoxib), Celebrex (celecoxib) and Bextra (valdecoxib). ... MedPage Today Efficacy and Safety of Rofecoxib 12.5 Mg and Celecoxib 200 Mg in Two ... - Feb 9, 2006 Objective: To compare the lower osteoarthritis (OA) dose of rofecoxib to the recommended dose of celecoxib in two identically designed studies. ... RedOrbit Rofecoxib for rheumatoid arthritis - Jul 1, 2007 Rheumatoid arthritis (RA) is a systemic auto – immune disorder, in which the synovial lining of many joints and tendon sheaths are persistently inflamed. ... Medscape Experts Point to Lessons Learned From Controversy Over Rofecoxib … - Jan 26, 2005 Chicago—Now that rofecoxib has been pulled from the market due to ... The recent controversy over rofecoxib and other COX-2 inhibitors has raised questions ... Journal of American Medical Association - Journal of American Medical Association... Risk Of Colorectal Polyps Recurrence Can Be Controlled By Rofecoxib - Sep 2, 2006 A new study shows that COX-2 inhibitor 'Rofecoxib' might be effective in controlling the recurrence of colorectal cancer. According to a new, 'A Randomized ... MedIndia Risk of death from rofecoxib in some trials may have been … - Apr 16, 2008 New technique could eliminate inherited mitochondrial disease — [26 Aug 2009] — Researchers have developed an experimental technique with the potential to ... Science Centric Effects of meloxicam and rofecoxib on psychomotor performance: A … - Nov 1, 2007 Objectives: To investigate the effects of meloxicam and rofecoxib on psychomotor performance in young, healthy volunteers. Materials and Methods: This study ... Free with registration - Indian Journal of Pharmacology - AccessMyLibrary.com Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of … - Feb 4, 2005 Background: Studies have postulated that cyclooxygenase-2 (COX- 2) selective inhibitors affect cardiovascular risk through various mechanisms. ... RedOrbit Rofecoxib Fails to Improve Outcomes After Colorectal Cancer Surgery: ... - Sep 16, 2008 By Ed Susman. STOCKHOLM, Sweden -- September 16, 2008 -- Results of a truncated trial of rofecoxib show that treatment with the cyclooxygenase 2 inhibitor ... DG News COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk - Sep 12, 2006 1 Celecoxib and rofecoxib were the first of these new agents to gain approval and, ... Then, in 2004, Merck withdrew rofecoxib from the market after its ... Journal of American Medical Association - Journal of American Medical Association... What next for pain relief? - Oct 2, 2005 Vioxx, also known by its generic name rofecoxib, was one of the cox-2 ... Indeed, cox-2s like rofecoxib, valdecoxib and celecoxib were regarded as ... Malaysia Star Use of Ghostwriters, Guest Authors Appears Frequent for Rofecoxib … - Apr 10, 2008 Newswise — An examination of medical articles about rofecoxib (a nonsteroidal ... "Recent litigation related to rofecoxib provided a unique opportunity to ... newswise.com Rofecoxib (Systemic).(Drug overview) - May 1, 2006 Rofecoxib (roe-fe-COKS-ib) is used to relieve some symptoms caused by arthritis, such as inflammation, swelling, stiffness, and joint pain. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com ROFECOXIB (Oral route) - roe-fe-KOX-ib.(Drug overview) - May 1, 2007 Rofecoxib is used to relieve some symptoms caused by arthritis, such as inflammation, swelling, stiffness, and joint pain. However, this medicine does not ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Rofecoxib regulates the expression of genes related to the matrix … - Aug 22, 2005 Xiao-Min Wang MD, PhD 1 , Tian-Xia Wu PhD 1 , Yun-Sil Lee DDS, MS 1 and Raymond A. Dionne DDS, PhD 1. Correspondence: Raymond A. Dionne, DDS, PhD, Bldg 10, ... Nature.com Rofecoxib Significantly Reduces The Risk Of Recurrence Of Colorectal ... - Jan 9, 2006 The use of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (Vioxx®) reduces the risk of colorectal adenomas, according to data being published in ... innovations report Celebrex risks cardiovascular problems - Otago - Apr 15, 2005 By the time rofecoxib was withdrawn last year, about 11000 of the patients in the IMMP cohorts had been followed up. It is the results from these patients ... scoop.co.nz Study: Most Patients Taking Vioxx (rofecoxib) Didn't Need It - Jan 24, 2005 By Peggy Peck, Senior Editor, MedPage Today. Review medical records of patients receiving COX-2 inhibitors to evaluate risks of GI bleeding. ... MedPage Today Rofecoxib, valdecoxib associated with increased risk of stroke. - Sep 1, 2008 Rofecoxib, valdecoxib associated with increased risk of stroke. A retrospective cohort study published in the journal Stroke demonstrated an increased risk ... $9.94 - Formulary - Alacra Store Meta-analysis Linked Rofecoxib, Not Other COX-2 Inhibitors, With... - Sep 22, 2006 September 22, 2006 — A meta-analysis of randomized trials of the cyclooxygenase-2 (COX-2) inhibitors rofecoxib, celecoxib, valdecoxib, parecoxib, ... Medscape 140,000 CHD cases in US linked to rofecoxib.(causes of Coronary Heart... - Jan 28, 2005 The withdrawn COX-2 inhibitor rofecoxib (Vioxx) may have been responsible for 140000 extra cases of serious CHD in the US, many of which were fatal, ... Free with registration - GP - AccessMyLibrary.com Vioxx successor should not be approved, advisers say . - Apr 17, 2007 Graham was a leading critic of Vioxx, a related drug also known as rofecoxib. could have a replay of what we had with rofecoxib," Graham said. ... Argus-Press - Google News Archive Arthritis Therapy; Rofecoxib was compared with nabumetone for … - May 10, 2006 2006 MAY 10 - (NewsRx.com) -- Researchers compare rofecoxib with nabumetone for the treatment of osteoarthritis in a recent issue of the Journal of Clinical ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Article: Valdecoxib banned, to hit 40 drug makers. - Economic Times (... - May 3, 2005 Cox-2 category drugs such as Rofecoxib and Valdecoxib had become popular because ... Pharmacology Update Rofecoxib Tablets and Oral Suspension (VioxxMerck ... Pay-Per-View - Economic Times - HighBeam Research Cyclooxygenase Inhibitors and Cardiovascular Risk—Reply - Feb 14, 2007 This would explain why rofecoxib and naproxen, which are not extensively ... The relative risk estimates for rofecoxib from studies conducted in the United ... Journal of American Medical Association - Journal of American Medical Association... Canada approves rofecoxib comeback - Jul 8, 2005 Ottawa, ON - Will rofecoxib (Vioxx, Merck) be making a comeback in Canada? Canadian regulators say that the company would have to file a new drug submission ... Medscape Vioxx should be allowed back on the market advises expert panel. - Aug 1, 2006 After Merck & Co. withdrew rofecoxib from the world marketplace on Sept. ... "There's no question [rofecoxib] increases cardiovascular risk compared to ... Free with registration - CMAJ: Canadian Medical Association... - AccessMyLibrary.com Responding to the Rofecoxib Withdrawal Crisis: A New Model for … - Feb 4, 2005 Background: We decided to inform our patients of the withdrawal of rofecoxib, one of the largest drug withdrawals in United States history, and instruct ... RedOrbit Excess heart disease and deaths caused by rofecoxib, study suggests - Jan 25, 2005 London, UK - In the 5+ years that it was on the market, rofecoxib (Vioxx, Merck & Co) may have been responsible for 88 000 to 140 00 excess cases of serious ... Medscape FDA Must Turn Over Vioxx Documents, Judge Rules - Oct 17, 2007 Weinberg requested information on Vioxx (rofecoxib) including clinical trial data, adverse event reports, Vioxx advertisements and correspondence between ... FDA news - FDA news (subscription) Genetics Plays Role in Side Effects Associated With Painkillers - Jan 5, 2006 The study looked at people taking two popular painkillers --rofecoxib (Vioxx, ... Previous studies have shown that rofecoxib and celecoxib result in a small ... EndoNurse Merck & Co's Vioxx lawsuit reinstated, firm may appeal decision. - Sep 11, 2008 Circuit Court of Appeals ruling that reinstated a law suit against the firm over the withdrawal of the product Vioxx (rofecoxib; Marketletters passim). ... $9.94 - Pharma Marketletter - Alacra Store FDA advisory committees recommend marketing of COX-2 inhibitors with... - Mar 1, 2005 Rofecoxib was voluntarily withdrawn from the market in September 2004 by Merck ... The panel was nearly split in its decision on the marketing of rofecoxib, ... Free with registration - Formulary - AccessMyLibrary.com … Trial of Tenoxicam Compared With Rofecoxib for Postoperative... - Jan 8, 2005 Two non-steroidal anti-inflammatory drugs, tenoxicam and rofecoxib, were compared ... Abdominal discomfort was significantly more common following rofecoxib ... RedOrbit Studies Provide New Evidence on Risks Associated with Cox-2 Inhibitors... - Sep 13, 2006 Although rofecoxib was withdrawn from world markets, celecoxib (marketed as ... "A dose-related risk was evident with rofecoxib (relative risk 1.33 with 25 ... DG News Canada approves rofecoxib comeback - Jul 11, 2005 Ottawa, ON - Will rofecoxib (Vioxx, Merck) be making a comeback in Canada? Canadian regulators say that the company would have to file a new drug submission ... Medscape Degree of Cardiovascular Risk from Use of Rofecoxib - Oct 1, 2005 Rofecoxib (Vioxx) was recently withdrawn from the market because of increased cardiovascular events in participants taking this drug as part of a trial of ... AAFP News Now Risk for Heart Attacks with Different NSAIDs - Apr 5, 2005 For example, rofecoxib was withdrawn from the market in September 2004 ... They considered rofecoxib dosages greater than 25 mg daily to be high dose. ... Annals of Internal Medicine Responding to the Rofecoxib Withdrawal Crisis: A New Model for … - Feb 1, 2005 Background: We decided to inform our patients of the withdrawal of rofecoxib, one of the largest drug withdrawals in United States history, and instruct ... Annals of Internal Medicine Lawsuits mount in wake of rofecoxib (Vioxx) withdrawal - May 1, 2005 Within 2 weeks of Merck & Co.'s decision to withdraw the anti-arthritis drug rofecoxib (Vioxx) because of its cardiovascular risks, lawyers filed 10 ... CMAJ … of alternative analgesics after rofecoxib withdrawal.(Special... - Jul 1, 2005 The objective of this study was to track the utilization of anti-inflammatory drugs among patients with active rofecoxib prescriptions at the time of market ... Free with registration - Formulary - AccessMyLibrary.com Cardiovascular Risks of Coxibs: The Orthopaedic Perspective - Jul 1, 2007 ...(Whitehouse Station, New Jersey) withdrew its blockbuster drug rofecoxib from the ... After just five years on the market, the annual sales of rofecoxib ... Journal of Bone and Joint Surgery - Journal of Bone and Joint Surgery... Risks From Drug in Some Trials May Have Been Misrepresented by Study … - Apr 10, 2008 The documents became available during litigation related to rofecoxib involving Merck, including internal company analyses and information provided by the ... newswise.com Do COX-2 Inhibitors Increase Congestive Heart Failure? - Feb 15, 2005 The increased risk in those receiving rofecoxib also was noted in the subgroup of ... The authors conclude that rofecoxib and nonselective NSAID use is ... AAFP News Now More Data Implicate Rofecoxib in Adverse Cardiac Events - Apr 18, 2005 With limited data from randomized prospective trials, much of our knowledge about the cardiovascular effects of cyclooxygenase (COX)-2 inhibitors is coming ... Medscape Centre set to take fresh look at Rofecoxib ban. - Feb 22, 2005 ...: The union health ministry will soon review the ban on painkiller Rofecoxib in the light of a US drug advisory panel's voting last weekend to allow the ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Independent Nurse: Celecoxib as likely to cause MI as rofecoxib.(Brief... - Mar 10, 2006 The COX-2 inhibitor celecoxib (Celebrex) increases the risk of MI as much as the withdrawn drug rofecoxib (Vioxx), according to a meta-analysis of four ... Free with registration - GP - AccessMyLibrary.com Risk of heart attack may increase with certain anti-inflammatory drugs - Jun 13, 2005 NSAIDS are commonly prescribed to relieve inflammation and pain, and include ibuprofen, diclofenac, naproxen, celecoxib and rofecoxib, plus a host of other ... Medical News Today - Medical News Today (press release) Has the withdrawal of rofecoxib (Vioxx) affected your prescribing... - Feb 1, 2005 ..."It certainly changed our habits. We've gone back to using more non-steroidals. A favorite drug in that regard was often Aleve, and now we can't use that ... Free with registration - Urology Times - AccessMyLibrary.com Gastroenterology; Rofecoxib and octreotide combine to stop gastric … - Jan 1, 2005 2005 JAN 1 - (NewsRx.com & NewsRx.net) -- Rofecoxib and octreotide combine to stop gastric cancer cell proliferation. "Our previous studies indicated that ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Are there differences in the renal effects of selective cyclo... - Jul 18, 2005 In one study, rofecoxib and the nonselective NSAID indomethacin were compared ... By contrast, in elderly patients with impaired renal function, rofecoxib ... Nature.com Cardiovascular events associated with rofecoxib in a colorectal... - Apr 7, 2005 The results from this study, known as the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial, provide further evidence that rofecoxib use is associated ... OnMedica Rofecoxib raises BP, but celecoxib poses little risk - Feb 28, 2005 By Graham Furness. This has been a painful year for big drugs. One year ago, selective serotonin reuptake inhibitors and cox-2 inhibitors were among the ... National Review of Medicine Alzheimer Disease; Rofecoxib not likely to delay progression from... - Jul 11, 2005 ..."Inflammatory mechanisms have been implicated" in AD, "and might be mediated via the COX-2 enzyme," scientists in the United States explained. ... Pay-Per-View - Biotech Business Week - Factiva, from Dow Jones Health Canada to seek public input on drugs - Mar 15, 2005 In related news, the FDA's advisory panel on COX-2 inhibitors recommended that rofecoxib, celecoxib (Celebrex) and valdecoxib (Bextra) stay on the market, ... CMAJ Primer: administrative health databases in observational studies of... - Feb 1, 2007 13 Although rofecoxib was associated with a reduction in the rate of ... The rate of acute MI was not significantly increased with rofecoxib use, ... Nature.com More studies on risks and benefits of COX-2 inhibitors published in … - Jan 21, 2005 The Celecoxib Rofecoxib Efficacy and Safety in Comorbodities Evaluation Trial ... "The market withdrawal of rofecoxib has brought to the forefront concerns ... PsychCentral.com Colorectal Polyps; Rofecoxib significantly reduces the risk of... - Sep 19, 2006 2006 SEP 19 - (NewsRx.com) -- The use of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (Vioxx) reduces the risk of colorectal adenomas, according to data ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Report of Specific Cardiovascular Outcomes of the ADVANTAGE Trial - Jul 19, 2005 Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. ... Annals of Internal Medicine St. Gallen Cantonal Hospital; Oral rofecoxib, diclofenac don't reduce... - Oct 26, 2005 2005 OCT 26 - (NewsRx.com) -- Oral treatment with rofecoxib or diclofenac fails to reduce morphine use in adult acute renal colic patients. ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Acute Renal Colic; Oral rofecoxib, diclofenac don't reduce morphine … - Oct 28, 2005 2005 OCT 28 - (NewsRx.com) -- Oral treatment with rofecoxib or diclofenac fails to reduce morphine use in adult acute renal colic patients. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Acute Renal Colic; Oral rofecoxib, diclofenac don't reduce morphine … - Oct 24, 2005 2005 OCT 24 - (NewsRx.com) -- Oral treatment with rofecoxib or diclofenac fails to reduce morphine use in adult acute renal colic patients. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones FDA panel sees role for COX-2s despite risks.(Clinical Rounds; Food... - Apr 1, 2005 For rofecoxib, the panel voted 17-15 that the overall risk-benefit profile ... Although the close votes for rofecoxib and valdecoxib are "challenging to ... Pay-Per-View - Skin & Allergy News - Factiva, from Dow Jones … cardiovascular damage known to arise from use of the painkiller... - Sep 20, 2005 Drugs such as rofecoxib, celecoxib (Celebrex) and valdecoxib (Bextra) avoid the gastrointestinal side effects by acting only on cox-2. ... News-Medical.net … of Sevilla; Selective COX-2 inhibitor rofecoxib delays gastric... - Feb 16, 2005 According to a study from Spain, "to elucidate the role of cyclooxygenase-2, we compared the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones … Drug Reaction; Selective COX-2 inhibitor rofecoxib delays gastric... - Feb 14, 2005 According to a study from Spain, "to elucidate the role of cyclooxygenase-2, we compared the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, ... Pay-Per-View - Proteomics Weekly - Factiva, from Dow Jones Vioxx: lessons for Health Canada and the FDA - Jul 19, 2005 Last fall the COX-2 inhibitor rofecoxib (Vioxx), a heavily marketed and successful drug ... Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. ... CMAJ APPROVe Off-Drug Extension - May 11, 2006 APPROVe was designed to evaluate the efficacy of rofecoxib 25 mg in preventing ... However, in the period beyond month 18, the relative risk for rofecoxib ... Free with registration - Business Wire - AccessMyLibrary.com Arthritis Drug – Rofecoxib , Found To Increase Heart Attack Risk - Feb 10, 2005 Based on findings of a recent study researchers say the arthritis drug rofecoxib (Vioxx) is found to increase the risk of heart attack. ... MedIndia InBrief: Rofecoxib statistics error.(Merck report on safety of Vioxx... - Jun 8, 2006 Merck has admitted a `statistical error' was made in one of the key papers on the safety of rofecoxib (Vioxx). The correction changed the p- value for one ... Free with registration - Pulse - AccessMyLibrary.com Clinical Trial Said to Have Been Marketing in Disguise - Aug 18, 2008 Explain to interested patients that the study found corporate documents showing that a trial comparing rofecoxib (Vioxx) with naproxen (Aleve) had been ... MedPage Today Osteoid Osteoma; Rofecoxib effective for pain caused by osteoid... - Feb 22, 2005 2005 FEB 22 - (NewsRx.com & NewsRx.net) -- Researchers from Spain reported in Orthopedics that rofecoxib was effective for pain caused by osteoid osteoma. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones COX-2 Inhibitors: Overview - Jun 16, 2005 The manufacturer withdrew rofecoxib (Vioxx) from the market following ... Market withdrawal of rofecoxib comes more than five years after its launch. ... RedOrbit Osteoid Osteoma; Rofecoxib effective for pain caused by osteoid... - Feb 26, 2005 2005 FEB 26 - (NewsRx.com & NewsRx.net) -- Researchers from Spain reported in Orthopedics that rofecoxib was effective for pain caused by osteoid osteoma. ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Are NSAIDs and selective cyclo-oxygenase 2 inhibitors associated with... - Dec 14, 2007 Although the evidence that rofecoxib use is associated with an increased risk of a ... With the exception of rofecoxib use, Scott et al. reported either no ... Nature.com Entire COX-2s class increases risk of MI - Apr 21, 2006 Newer COX-2 inhibitors increase the risk of MI as much as rofecoxib, ... Current use of rofecoxib (Vioxx), celecoxib (Celebrex) and diclofenac were ... Pay-Per-View - GP - Factiva, from Dow Jones NSAID use may increase stroke risk - May 31, 2006 The research team found that patients who used rofecoxib or etoricoxib, ... Moreover, the association between rofecoxib or etoricoxib and stroke risk tended ... Medwire (subscription) Aspirin might prevent Vioxx cardiac damage - Sep 7, 2005 Drugs such as rofecoxib, celecoxib (CelebrexÆ) and valdecoxib (BextraÆ) avoid the gastrointestinal side effects by acting only on cox-2. ... PsychCentral.com Rofecoxib, diclofenac, and indomethacin increase risk of CVD.(Patient... - Dec 1, 2006 Rofecoxib (Vioxx), diclofenac (Voltaren, Cataflam), and indomethacin (Indocin) are associated with a significant increased risk of cardiovascular disease ... $4.95 - Journal of Family Practice - ECNext Coxibs, Science, and the Public Trust - Jan 24, 2005 Patients randomized to rofecoxib were found to have an approximately 2-fold increase in ... 4 The removal of rofecoxib 5 years and many studies after its ... Archives of Internal Medicine Cardiovascular Risk and Inhibition of Cyclooxygenase A Systematic … - Oct 4, 2006 Context Evidence that rofecoxib increases the risk of myocardial ... A dose-related risk was evident with rofecoxib, summary relative risk with 25 mg/d or ... Journal of American Medical Association - Journal of American Medical Association... Celecoxib and rofecoxib have same heart risk - Apr 22, 2005 The cox-2 inhibitor celecoxib (Celebrex) and rofecoxib (Vioxx) cause a similar number of adverse cardiovascular events, according to a New Zealand study. ... Pay-Per-View - GP - Factiva, from Dow Jones Regular Use Of Selective COX-2 Inhibitors Decreases Risk Of Breast … - Feb 3, 2006 ...a daily dose of 200 mg celecoxib reduced the risk of breast cancer by 83% and a daily dose of 25 mg rofecoxib reduced the risk of breast cancer by 64%. ... Medical News Today - Medical News Today (press release) Aspirin May Prevent Colon Cancer Recurrence: Presented at ASCO - May 20, 2005 Rofecoxib (Vioxx) was voluntarily withdrawn from the market last fall after a study of colorectal polyp prevention showed a higher risk of cardiovascular ... DG News Latest Vioxx plaintiff fails to prove case. - Jan 29, 2007 ...verdicts in cases filed by two plaintiffs who alleged that Merck & Co's now withdrawn COX-2 drug Vioxx (rofecoxib) contributed to their heart attacks. ... $9.94 - Pharma Marketletter - Alacra Store COX-2 inhibitors associated with varying risk of MI.(Medication... - Jan 1, 2005 The study included 1718 patients (celecoxib users, n=18; rofecoxib users, ... When compared with celecoxib, rofecoxib was associated with nearly a 3-fold ... Free with registration - Formulary - AccessMyLibrary.com Brand Names/Synonyms: Rofecoxib is also known by the following brand names and/or synonymsCCRIS 8967; CHEMBANK1837; MK 0966; MK 0996; MK 966; MK 996; Rofecoxib; Vioxx Drug Category: Rofecoxib is categorized under the following by the FDA: Anti-inflammatory Agents; Nonsteroidal Antiinflammatory Agents (NSAIDs); ATC:M01AH02 Dosage Forms: Tablets, oral suspension Absorption: The mean oral bioavailability of VIOXX at therapeutically recommended doses of 12.5, 25, and 50 mg is approximately 93% Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |